|Home | About | Journals | Submit | Contact Us | Français|
Changes in consensus arylamine N-acetyltransferase (NAT) gene nomenclature determined at the 2007 international NAT workshop include: 1) Alleles in all species except mouse and rat are all uppercase. For mouse and rat, the first letter is upper case followed by lower case. 2) The nomenclature system is now species-specific. Thus, NAT2*1 (chicken), NAT2*2 & NAT2*3 (rabbit), Nat2*8 Nat2*9, Nat2*22 & Nat2*23 (mouse), NAT2*15, NAT2*16A & NAT2*16B (Syrian hamster), and NAT2*20, NAT2*21A & NAT2*21B (rat) are retired and renumbered within a species. A species modifier incorporated into the allele designation is written in upper case Roman font, e.g., (MOUSE)Nat1*1 is now the reference Nat1 allele in mouse; and 3) The NAT website also can now be accessed at a webbalias address: http://N-acetyltransferasenomenclature.louisville.edu. New NAT alleles should continue to be submitted to the NAT nomenclature committee for inclusion on the website to ensure proper categorization and to continue consistency in nomenclature.
Consensus gene nomenclature is necessary to report and interpret the results of human epidemiological studies, as well as to perform meta analyses and/or compare the results of different studies. Towards that end, consensus nomenclature for arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) alleles was published in 1995 . Subsequently, many additional NAT1 and NAT2 alleles have been identified in humans and in other species. In the rat and mouse, a third arylamine N-acetyltransferase gene (NAT3) has been discovered and various NAT3 alleles also have been identified.
Sessions on arylamine N-acetyltransferase gene nomenclature have been held at each of the four International Arylamine N-acetyltransferase Workshops held in Kuranda, Australia (1998), Oxford, UK (2001), Vancouver, Canada (2004) and Alexandroupolis, Greece (2007). An arylamine N-acetyltransferase gene nomenclature committee, established at the first workshop in 1998 and reviewed at subsequent workshops, assesses what changes need to be made in the nomenclature and serves as a clearing house for naming new arylamine N-acetyltransferase alleles. Scientific correspondence reporting establishment of the international nomenclature committee, updates to the arylamine N-acetyltransferase gene nomenclature, and the initiation of a consensus arylamine N-acetyltransferase gene nomenclature website (http://www.louisville.edu/medschool/pharmacology/NAT.html) was published in 2000 .
Since 2000, the arylamine N-acetyltransferase gene nomenclature committee (now expanded and consisting of the authors of this report) continues to maintain the website and update the nomenclature listings as new genes and alleles are identified. The committee considers the most “functionally significant” single nucleotide polymorphism when assigning human NAT2 alleles. Thus, human NAT2 alleles containing 341T>C (I114T) are assigned to the NAT2*5 cluster, alleles containing 590G>A (R197Q) are assigned to the NAT2*6 cluster, and so on. This is consistent with the original consensus NAT2 nomenclature  and with general recommendations for human gene nomenclature.
At the most recent arylamine N-acetyltransferase workshop held September 2007 in Alexandroupolis, several decisions were made that have now been implemented by the nomenclature committee and reflected at the arylamine N-acetyltransferase gene nomenclature website. These changes are as follows:
The authors acknowledge the helpful input of Dr. Elspeth Bruford, Head of the Human Gene Nomenclature Committee, European Bioinformatics Institute, Hinxton, Cambridge, UK.
Sponsorship: DWH is supported by R01-CA034627 from the National Cancer Institute; RFM is supported by the Australian National Health and Medical Research Council grants number 401563 and 511023 and the Department of Veteran Affairs grant number 303155; ES is supported by Programme Grant 067887 from the Wellcome Trust.